Get started
Astellas Pharma, Inc.Astellas Pharma, Inc.Astellas Pharma, Inc.

Astellas Pharma, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ALPMY chart


Full chart

ALPMY upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪15.92 B‬ USD
Dividend yield (indicated)
3.78%
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.21 USD
Net income (FY)
‪117.88 M‬ USD
Revenue (FY)
‪11.09 B‬ USD
Shares float
—
Beta (1Y)
−0.04

About ASTELLAS PHARMA


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Naoki Okamura
Website
astellas.com
Headquarters
Tokyo
Founded
1923
FIGI
BBG000NVS6W6
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products: XTANDI, PADCEV, XOSPATA, VYLOY, VEOZAH, IZERVAY, EVRENZO, BETANIS and PROGRAF. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ALPMY news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as ALPMY.